Latest Epidermal growth factor receptor Stories
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute. "We've revealed multiple new signaling pathways that regulate cell death," said Sally Kornbluth, PhD, vice dean of Basic Science and professor of Pharmacology and Cancer Biology at Duke...
Union with Shc keeps potential troublemaker away from bad company and out of the nucleus A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology. Shc, pronounced "schick," plays a key role in activating signals which lead to cell proliferation (and cancer)...
Watch the video "Chemotherapy Drugs Getting Better at Targeting Cancer Cells" redOrbit Staff & Wire Reports - Your Universe Online Changing the shape of chemotherapy drug nanoparticles to make them rod-shaped rather than spherical can enhance their effectiveness in targeting and treating breast cancer cells by as much as 10,000-fold, according to new research from bioengineers at the University of California, Santa Barbara (UCSB). As part of the research, a team led by Samir...
University of Akron For scientists to improve cancer treatments with targeted therapeutic drugs, they need to be able to see proteins prevalent in the cancer cells. This has been impossible, until now. Thanks to a new microscopy technique, University of Akron researcher Dr. Adam Smith, assistant professor of chemistry, has observed how clusters of epidermal growth factor receptor (EGFR) — a protein abundant in lung and colon cancers, glioblastoma and others — malfunctions in cancer...
A new approach mimicking the body's natural defenses could help treat a therapy-resistant breast cancer Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are...
Transforming AvidBiologics' pipeline into one of the most competitive in the industry. TORONTO, Jan. 29, 2013 /PRNewswire/ - AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel ADCs for the treatment of cancer. The agreement is a partnership under which the three novel, tumor-specific antibodies, which were generated as part of the...
HILDEN, Germany and GERMANTOWN, Maryland, January 15, 2013 /PRNewswire/ -- - U.S. submission of therascreen(R) EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyrosine kinase inhibitor developed by Boehringer Ingelheim - Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer - QIAGEN continues to expand Personalized Healthcare portfolio and content menu...
RIDGEFIELD, Conn., Jan. 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for afatinib is currently under review for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth...
Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the Fox Chase Cancer Center recently discovered a novel method of improving cancer drugs, where they could block a specific pathway in the cell and provide an easier way for drugs to eliminate tumors. According to the American Cancer Society, cancer occurs when there is uncontrolled growth and expansion of abnormal cells. It is caused by external factors (such as chemicals, infectious organisms, radiation, and...
A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care. “We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,” Bunn says. The review describes the shift from blanketing lung...
